Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Roivant Sciences Ltd. Common Shares
ROIV | US
27.41
USD-0.73
-2.59%
ROIV | US
Loading StockChartView...
About Roivant Sciences Ltd. Common Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
27.41
Open
28.24
High
28.32
Low
27.06
Roivant Sciences Ltd. a commercial-stage biopharmaceutical company engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses discovery-stage companies and health technology startups. It develops VTAMA a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402 the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101 an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London the United Kingdom.
View LessROIV | US
Risk
32.1
Sharpe
3.86
Luna's Score
64/100
Recommendation
Hold
Luna says (ROIV | US)
What's Working
Largecap (10B - 200B USD)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
31.3%1 month
32.1%3 months
55.6%6 months
46.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
2.08
Fwd. PE
-
Price to book
1.62
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
0.75
Ent. to rev.
22.21
PEG
-
Other Fundamentals
EBITDA
-1.02B
MarketCap
20.27B
MarketCap(USD)
20.27B
Div. yield
-
Op. margin
-402.44
Erngs. growth
-
Rev. growth
155.00
Ret. on equity
127.71
Short ratio
5.18
Short perc.
9.18
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.12
Range1M
4.23
Range3M
9.35
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.21
Price X volume
153.13M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.75 | 0.53 | Expensive |
| Ent. to Revenue | 22.21 | 3,967.00 | Cheaper |
| PE Ratio | 2.08 | 41.03 | Cheaper |
| Price to Book | 1.62 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 55.58 | 72.80 | Lower Risk |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 20.27B | 3.66B | Market Leader |
